Elite Diagnostic Limited(ELITE)

Unaudited financials for the nine months ended March 31, 2026:

Elite Diagnostic Limited (ELITE) for the nine months ended March 31, 2026, reported a 4% increase in Income totaling $650.78 million compared to $628.82 million in the corresponding period last year. Income for the third quarter had a 7% increase to close at $241.93 million compared to $227.09 million for the comparable quarter of 2025.

Year to date, direct cost amounted to $148.08 million (2025: $159.28 million), a 7% decrease from the prior year. Consequently, gross profit increased by 7% to $502.70 million compared to $469.54 million for the nine months ended March 31, 2025. The company booked gross profit of $187.34 million for the third quarter versus $177.18 million reported for the similar quarter of 2025.

Year to date, administrative expenses increased by 1% to close at $311.57 million (2025: $307.66 million), while depreciation & amortization increased by 5% from $126.85 million in 2025 to $133.52 million in the period under review. As a result, operating profit for the nine months ended March 31, 2026 amounted to $57.61 million, a 64% increase relative to $35.03 million reported in 2025.

Foreign exchange gain for the nine months ended March 31, 2026, amounted to $1.56 million (2025: gain of $2.07 million). Foreign exchange gain for the third quarter amounted to $380,000 (2025: gain of $968,000). Finance costs totaled $33.74 million, a 21% increase from the corresponding period last year (2025: $27.96 million).

Profit Before Tax for the nine months ended March 31, 2026, amounted to $26.39 million, a 188% increase relative to $9.15 million reported in 2025. Profit Before Tax for the third quarter amounted to $25.22 million (2025: $26.80 million).

Tax charge incurred for the nine months ended March 31, 2026 amounted to $863,000 (2025: $475,000). Net Profit for the nine months amounted to $25.53 million (2025: Net Profit of $8.68 million). For the third quarter, Net Profit was $24.91 million (2025: $26.33 million).

Consequently, Earnings Per Share for the nine months amounted to $0.07 (2025: EPS: $0.02), while Earnings Per Share for the quarter totaled $0.07 (2025: EPS: $0.07). The twelve month trailing EPS was $0.14 and the number of shares used in these calculations was 353,400,000. Notably, ELITE’s stock price closed the trading period on May 13, 2026 at a price of $1.38 with a corresponding P/E ratio of 9.86x.

Balance Sheet Highlights

The company’s assets totaled $1.09 billion (2025: $1.02 billion). The movement in total assets was mainly attributable to a $145.17 million increase in ‘Cash and bank balances’ amounting to $204.07 million (2025: $58.90 million), which was offset by a $57.64 million decline in ‘Property, plant and equipment’ amounting to $637.94 million (2025: $695.57 million).

Shareholders’ equity was $568.53 million (2025: $519.66 million), representing a book value per share of $1.61 (2025: $1.47).

Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.